Formulation and Drug Delivery

Emergent to Acquire Specialty Vaccines Company PaxVax

August 17, 2018

The acquisition is expected to support Emergent BioSolutions’ focus on public health threats and emerging infectious disease.

Leaf Expression Systems’ Facility Begins Operations

August 17, 2018

The company’s purpose-built facility in Norwich, United Kingdom specializes in plant-based expression of proteins, metabolites, and complex natural products.

Pfizer, BioNTech to Develop mRNA-based Flu Vaccines

August 16, 2018

Pharmaceutical Technology's In the Lab eNewsletter

The companies entered a multi-year R&D collaboration to develop mRNA-based flu vaccines.

FDA Approves Drug Product Manufacturing for Samsung BioLogics

August 14, 2018

Drug product approval from FDA follows previous approvals from European and Japanese authorities.

FDA Approves First-of-its-Kind RNA Therapy

August 13, 2018

The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

Ebola Vaccinations Begin in Response to Congo’s Last Outbreak

August 09, 2018

Ebola vaccinations by the World Health Organization began in North Kivu, Democratic Republic of the Congo, one week after the country’s latest outbreak.

Innovating Lifecycle Management with Data-Driven and Enabling Technologies

August 07, 2018

Pharmaceutical companies are developing new strategies to address the ever-increasing development costs for new drug therapies and maximize the value of their existing drug portfolio.

EC Approves Pfizer’s Biosimilar to Roche’s Herceptin

August 07, 2018

The European Commission (EC) approved Pfizer’s Trazimera (trastuzumab), a biosimilar to Roche’s Herceptin, to treat certain breast and gastric cancers.

Regeneron, bluebird bio Partner on Cell Therapy Development

August 06, 2018

The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.

Developing Capsules for DPIs

August 03, 2018

Formulation characteristics must be optimized, following device selection, to achieve the desired performance for the capsule loaded in the dry powder inhaler.